Forbes July 5, 2024
Robert Hart

Topline

A class of diabetes and weight loss drugs that includes Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro could also help protect against a variety of cancers, according to new research published Friday, adding to mounting evidence the injections offer numerous additional health benefits as pressure builds for insurers and public health providers to cover the popular medication in spite of persistent shortages and cost concerns.

Key Facts

Surprising Fact

While GLP-1RAs were associated with a decreased risk for most obesity-associated cancers studied compared to other standard diabetes treatments, the researchers said drugs were also associated with a risk of developing some cancers. Compared to patients on metformin, patients taking GLP-1RAs had a higher risk of kidney cancers, the researchers...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Provider, Survey / Study, Trends
Related Articles:
In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi's CAD drug Enjaymo
Pharma Pulse 10/3/24: Data Collection Complexities, 8 Things You May Not Know About Breast Cancer & more
New Techniques Make RNA Accessible to Study Variants of Uncertain Significance
Comprehensive strategies for prescription drug cost management
Gilead strikes deal to expand HIV drug access in 120 countries

Share This Article